Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
8.38
+0.28 (3.40%)
At close: Mar 9, 2026, 4:00 PM EDT
8.40
+0.03 (0.30%)
After-hours: Mar 9, 2026, 4:10 PM EDT
Kyverna Therapeutics Employees
Kyverna Therapeutics had 112 employees as of December 31, 2024. The number of employees increased by 16 or 16.67% compared to the previous year.
Employees
112
Change (1Y)
16
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,248,000
Market Cap
479.89M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 112 | 16 | 16.67% |
| Dec 31, 2023 | 96 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| REGENXBIO | 353 |
| Lyell Immunopharma | 300 |
| Rocket Pharmaceuticals | 202 |
| Entrada Therapeutics | 152 |
| Century Therapeutics | 150 |
| Lineage Cell Therapeutics | 77 |
| Assembly Biosciences | 73 |
KYTX News
- 4 days ago - Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 - GlobeNewsWire
- 6 days ago - Kyverna Therapeutics to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 6 days ago - Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution - Seeking Alpha
- 13 days ago - Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors - GlobeNewsWire
- 4 weeks ago - Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer - GlobeNewsWire
- 2 months ago - Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference - GlobeNewsWire
- 2 months ago - Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies - Seeking Alpha